Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Experimental cytokine modulation therapy of inflammatory bowel disease (Crohn's disease and ulcerative colitis)

References to Primarv Literature

• HODGSON H: One disease or two? In: Inflammatory BowelDiseases. Allan RN et al. (Eds.), Churchill Livingstone, London (1990):121–126.
   Google Scholar
• MACPHERSON A, KHOO U, FORGACS I, PHILPOTT-HOWARD J, BJARNASON I: Mucosal antibodies in inflam-matory bowel disease are directed against intestinal bacteria. Gut (1996) 38:365–375.
   PubMed Web of Science ®Google Scholar
• BLASER M, MILLER R, LACHER J, SINGLETON J: Patients with active Crohn's disease have elevated serum anti-bodies to seven enteric microbial pathogens. Gastroen-terology (1984) 87:888–894.
   PubMed Web of Science ®Google Scholar
• MORRISON D, RYAN J: Endotoxins and disease mecha-nisms. Ann. Rev. Med. (1987) 38:417–432.
   PubMed Web of Science ®Google Scholar
• KOTZIN B, LEUNG D, KAPPLER J, MARRACK P: Superan-tigens and their potential role in human disease. Adv. Immunol. (1993) 54:99–166.
   PubMed Web of Science ®Google Scholar
• BENDTZEN K, HANSEN M, ROSS C, POULSEN L, SVENSON M: Cytokines and autoantibodies to cytokines. Stem Cells (1995) 13:206–222.
   PubMed Web of Science ®Google Scholar
• BALKWILL F, BURKE F: The cytokine network. Immunol. Today (1989) 10:299–304.
   PubMedGoogle Scholar
• STEVENS C, WALZ G, SINGARAM C et al.: Tumor necrosis factor a, interleukin-113, and interleukin-6 in inflamma-tory bowel disease. Dig. Dis. Sci. (1992) 818:26.
   Google Scholar
• BRYNSKOV J, TVEDE N, ANDERSEN C, VILLEN M: In-creased concentrations of interleukin-10, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut (1992) 33:55–58.
   PubMed Web of Science ®Google Scholar
• LIGUMSKY M: Role of interleukin-1 in inflammatorybowel disease - enhanced production during active disease. Gut (1990) 31:686–689.
   PubMed Web of Science ®Google Scholar
• SHANAHAN F, BERNSTEIN C: Interleukin-8, neutrophiLs,and acute inflammation. Gastroenterology (1992) 103:341–343.
   PubMedGoogle Scholar
• SCHAUFELBERGER H, UHR M, MCGUCKIN C et al.: Platelets In ulcerative colitis express functional interleukin-1 and interleukin-8 receptors. Eur. J. Clin. Invest. (1994) 24:656–663.
   PubMed Web of Science ®Google Scholar
• GROSS V, ANDUS T, CAESAR I, ROTH M, SCHOLMERICH J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology (1992) 102:514–519.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, HEINIG T, PANZER U et al.: Impaired response of activated mononuclear phagocytes to in-terleukin-4 in inflammatory bowel disease. Gastroen-terology (1996) 108:21–33.
   Web of Science ®Google Scholar
• SCHREIBER S, HEINIG T, THIELE H, RAEDLER A: Im-munoregulatory role of interleukin-10 In patients with Inflammatory bowel disease. Gastroenterology (1995) 108:1434–1444.
   PubMed Web of Science ®Google Scholar
• KUHN R, LOHLER J, RENNICK D, RAJEWSKY K, MULLER W:Interleukin-10-defident mice develop chronic entero-colitis. Cell (1993) 75:263–274.
   PubMed Web of Science ®Google Scholar
• COMINELLI F, NAST C, DUCHINI A, LEE M: RecombinantInterleukin-1 receptor antagonist blocks the proinflam-matory activity of endogenous interleukin-1 in rabbit Immune colitis. Gastroenterology (1992) 103:65–71.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA T, MITSUYAMA K, TOYONAGA A, SASAKI E,TANIKAWA K: Colonic mucosal interleukin-1 receptor antagonist in inflammatory bowel disease. Digestion (1994) 55:368–373.
   PubMed Web of Science ®Google Scholar
• ELSON C, SARTOR R, TENNYSON G, RIDDEL R: Experi-mental models of inflammatory bowel disease. Gas-troenterology (1996) 109:1344–1367.
   Web of Science ®Google Scholar
• SADLACK B, MERZ H, SCHORLE H et al.: Ulcerative coli-tis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 75:253–261.
   PubMed Web of Science ®Google Scholar
• HANAUER S: Inflammatory bowel disease. New Engl. J. Med. (1996) 334:841–848.
   PubMed Web of Science ®Google Scholar
• CHOI P, TARGAN S: Immunomodulator therapy in in-flammatory bowel disease. Dig. Dir. Sci. (1994) 39:1885–1892.
   PubMed Web of Science ®Google Scholar
• SANDBORN W: A review of immune modifier therapyfor inflammatory bowel disease: Azathioprine, 6-mer-captopurine, cyclosporine, and methotrexate. Am, J. Gastroenterol. (1996) 91:423–433.
   PubMed Web of Science ®Google Scholar
• DINARELLO C: Biologic basis for interleukin-1 in disease. Blood (1996) 87:2095–2147.
   PubMed Web of Science ®Google Scholar
• AREND W: Interleukin-1 receptor antagonist Adv. Im-munol. (1993) 40:365–394.
   Google Scholar
• BENDTZEN K: Cytokines and natural regulators of cy-tokines. Immunol. Lett. (1994) 43:111–123.
   PubMed Web of Science ®Google Scholar
• BRYNSKOV J. NIELSEN O, AHNFELT-RCNNE I, BENDTZEN K: Cytokines (inununoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig. Dis. (1994) 12:290–304.
   PubMed Web of Science ®Google Scholar
• COMINELLI F, NAST C, CLARK B et al.: Interleukin-1 (I1-1)gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J. Clin. Invest. (1990) 86:972–980.
   PubMed Web of Science ®Google Scholar
• LAURITSEN K, LAURSEN L, BUKHAVE K, RASK-MADSEN J:Inflammatory intermediaries in inflammatory bowel disease. Int. J. Colorect. Dis. (1989) 4:75–90.
   PubMed Web of Science ®Google Scholar
• NIELSEN O: In vitro studies on the significance of arachidonate metabolism and other oxidative proc-esses in the inflammatory response of human neutro-phils and macrophages - with special reference to chronic inflammatory bowel disease. Scand.J. Gastroen-terol. (1988) 23\(Suppl. 150):1–21.
   Google Scholar
• ISAACS K, SARTOR R, HASKILL S: Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology (1992) 103:1587–1595.
   PubMed Web of Science ®Google Scholar
• CAPPELLO M, KESHAV S, PRINCE C, JEWELL D, GORDONS: Detection of mRNAs for macrophage products in Inflammatory bowel disease by in situ hybridisation. Gut (1992) 33:1214–1219.
   PubMed Web of Science ®Google Scholar
• MAHIDA Y, WU K, JEWELL D: Enhanced production ofinterleukin-113 by mononuclear cells isolated from mu-cosa with active ulcerative colitis or Crohn's disease. Gut (1989) 30:835–8.
   PubMed Web of Science ®Google Scholar
• ARZT E, SAUER J, POLLMACHER T et al.: Glucocorticeidssuppress interleukin-1 receptor antagonist synthesis following induction by endotoxin. Endocrinology (1994) 134:672–677.
   PubMed Web of Science ®Google Scholar
• MANSFIELD J, HOLDEN H, TARLOW J et al.: Novel genetic association between ulcerative colitis and the anti-in-flanunatory cytokine interleukin-1 receptor antagonist. Gastroenterology (1994) 106:637–642.
   PubMed Web of Science ®Google Scholar
• SVENSON M, NEDERGAARD S, HEEGAARD P et al.: Differ-ential binding of human interleukin-1 (11-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors. Eur. J. Immunol. (1995) 25:2842–2850.
   PubMed Web of Science ®Google Scholar
• MARX J: How the glucocorticoids suppress immunity.Science (1995) 270:232–233.
   PubMed Web of Science ®Google Scholar
• MULLIN G, LAZENBY A, HARRIS M, BAYLESS T, JAMES S:Increased interleukin-2 messenger RNA in the intesti-nal mucosal lesions of Crohn's disease, but not ulcera-tive colitis. Gastroenterology (1992) 102: 1620-1627.
   Google Scholar
• AKIRA S, TAGA T, KISHIMOTO T: Interleukin-6 in biologyand medicine. Adv. Immunol. (1993) 54:1–78.
   PubMed Web of Science ®Google Scholar
• BRYNSKOVJ: Cyclosporin in Crohn' s disease: Therapeu-tic and pathogenetic implications. Dan. Med. Bull. (1994) 41:332–344.
   PubMed Web of Science ®Google Scholar
• BRYNSKOV J, FREUND F, CAMPIANI M, KAMPMANN J: Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. Scand.J. Gastroenterol. (1992) 27:961–967.
   PubMed Web of Science ®Google Scholar
• BANCHERAU J, BRIERE F, GALIZZI J, MIOSSEC P, ROUSSET F: Human interleukin-4. J. Lipid Med. Cell Signal. (1994) 9:43–53.
   PubMedGoogle Scholar
• MITSUYAMA K, SATA M, TANIKAWA K: Significance of interleulcin-6 in patients with inflammatory bowel dis-ease. Gastroenterol. Jpn. (1991) 26:20–28.
   PubMedGoogle Scholar
• IZZO R S, WITKON K, CHEN Al et al.: Neutrophil-activat-ing peptide (Interleukin-8) in colonic mucosa from patients with Crohn's disease. Scand. J. Gastroenterol. (1993) 28:296–300.
   PubMed Web of Science ®Google Scholar
• MAHIDA Y, CESKA M, EFFENBERGER F et al.: Enhancedsynthesis of neutrophil-activating peptide-1/inter-leukin-8 in active ulcerative colitis. Clin. Sci, (1992) 21:273–275.
   Google Scholar
• ECKMANN L, CHAE JUNG H, SCHÜRER-MALY C et al.: Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of EL-8. Gas-troenterology (1993) 105: 1689-1697.
   Google Scholar
• GROSS V, ANDUS T, HAIG R et al.: Regulation of inter-leukin-8 production in a human colon epithelial cell line (HT-29). Gastroenterology (1996) 107:653–661.
   Google Scholar
• CASINI-RAGGI V, MONSACCHI L, VOSBECK K et al.: Anti-inflammatory effect of GCP 47969A, a novel inhibitor of proinflammatory cytokine synthesis, in rabbit im-mune colitis. Gastroenterology (1995) 109:812–818.
   PubMed Web of Science ®Google Scholar
• MOSMANN T: Properties and functions of interleukin-10. Adv. Immunol. (1994) 56:1–26.
   PubMed Web of Science ®Google Scholar
• FIORENTINO D, ZLOTNLK A, VIERA P et al.: IL-10 acts onthe antigen presenting cell to inhibit cytokine produc-tion by Thl cells. J. Immunol. (1991) 146:3444–3451.
   PubMed Web of Science ®Google Scholar
• KEITH J, ALBERT L, SONIS S, PFEIFFER C, SCHAUB R:11-11,a pleiotropic cytokine: exciting new effects of 11-11 on gastrointestinal mucosal biology. Stem Cells (1994) 12:79–90.
   PubMed Web of Science ®Google Scholar
• TRINCHIERI G: Interleulcin-12: A proinflanunatory cy-tokine with immunoregulatory functions that bridge Innate resistance and antigen-specific adaptive immu-nity. Ann. Rev. Immunol. (1995) 13:251–276.
   PubMed Web of Science ®Google Scholar
• TREMBLEAU S. GERMANN T, GATELY M, ADORINI L: The role of IL-12 in the induction of organ-specific auto-im-mune diseases. Immunol. Today (1995) 16:383–386.
   PubMedGoogle Scholar
• DUCHMANN R, KAISER I, HERMANN E et al,: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (EBD). Clin. Exp. Immunol. (1995) 102:448–455.
   PubMed Web of Science ®Google Scholar
• NEURATH M, FUSS I, KELSALL B et al.: Antibodies to interleukin-12 abrogate established experimental coli-tis in mice. J. E. Med. (1995) 182:1281–1290.
   PubMed Web of Science ®Google Scholar
• MACDONALD T, HUTCHINGS P, CHOY M, MURCH S, COOKE A: Tumor necrosis factor alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immu-nol. (1990) 81:301–305.
   PubMed Web of Science ®Google Scholar
• REINECKER K, WITTHOEFT T, PFLUEGLER, SCHREIBER S, MACDERMOTT R: Enhanced secretion of tumor necrosis factor alpha, IL-6, and II.-113 by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. (1993) 94:174–181.
   Google Scholar
• CAPPELLO M, KESHAV S, PRINCE C, JEWELL D, GORDON S: Detection of mRNAs for macrophage products in Inflammatory bowel disease. Gut (1992) 33:1214–1219.
   PubMed Web of Science ®Google Scholar
• BRAEGGER C, NICHOLLS S, MURCH S, STEPHENS S, MAC-DONALD T: Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (1992) 339:89–91.
   PubMed Web of Science ®Google Scholar
• HYAMS J, TREEM W, EDDY E, WYZGA N, MOORE R: Tumornecrosis factor-a is not elevated in children with inflam-matory bowel disease. J. Pediatr. Gastroenterol. Nutr. (1991) 12:233–236.
   PubMed Web of Science ®Google Scholar
• HADZISELIMOVIC F, EMMONS L, GALLATI H: Soluble tumor necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treat-ment of inflammatory bowel disease. Gut (1995) 37:260–262.
   PubMed Web of Science ®Google Scholar
• KNIGHT D, TRINH H, LE J: Construction and initialcharacterisation of a mouse-human anti-TNF antibody. Mot Immunol. (1993) 30:1443–1453.
   Web of Science ®Google Scholar
• VAN DULLEMEN H, VAN DEVENTER S, HOMMES D et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroen-terology (1996) 109:129–135.
   Web of Science ®Google Scholar
• SARTOR R: Cytokines in intestinal inflammation: Patho-phys iological and clinical considerations. Gastroenterol-ogy (1994) 106:533–539.
   PubMed Web of Science ®Google Scholar
• PULLMAN W, ELSBURY S, KOBAYASHI M, HAPEL A, DOE W: Enhanced mucosal cytokine production in inflam-matory bowel disease. Gastroenterology (1992) 102:529–537.
   PubMed Web of Science ®Google Scholar